M
Miguel Angel Moreno
Publications - 9
Citations - 6872
Miguel Angel Moreno is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 3 publications receiving 6197 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rafael Rosell,Teresa Moran,Cristina Queralt,Rut Porta,Felipe Cardenal,Carlos Camps,Margarita Majem,Guillermo Lopez-Vivanco,Dolores Isla,Mariano Provencio,A. Insa,Bartomeu Massuti,José Luis González-Larriba,Luis Paz-Ares,Isabel Bover,Rosario García-Campelo,Miguel Angel Moreno,Silvia Catot,Christian Rolfo,Noemi Reguart,Ramon Palmero,Jose Miguel Sanchez,Roman Bastus,Clara Mayo,Jordi Bertran-Alamillo,Miguel Angel Molina,Jose Javier Sanchez,Miquel Taron +27 more
TL;DR: Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment, and the association between the mutations and the outcome of erlotinib treatment is analyzed.
Journal ArticleDOI
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies
Teresa Moran,J. Wei,M. Cobo,X. Qian,Manuel Domine,Z. Zou,Isabel Bover,Liang Wang,Mariano Provencio,L. Yu,Imane Chaib,C. You,B. Massuti,Y. Song,A. Vergnenegre,H. Lu,Guillermo Lopez-Vivanco,W. Hu,Gilles Robinet,J. Yan,A. Insa,X. Xu,Margarita Majem,X. Chen,R. de las Peñas,Niki Karachaliou,M.A. Sala,Q. Wu,Dolores Isla,Y. Zhou,Nathalie Baize,F. Zhang,J. Garde,P. Germonpre,S. Rauh,H. ALHusaini,Maria Sanchez-Ronco,Ana Drozdowskyj,Jose Javier Sanchez,Carlos Camps,B. Liu,Rafael Rosell,B. Colinet,J. De Greve,H. Chen,J. Du,Y. Gao,J. Hu,W. Kong,L. Li,R. Li,X. Li,J. Liu,W. Ren,L. Wen,X. Xiao,J. Yang,M. Yang,Y. Yang,J. Yin,X. Yue,J. Zhang,L. Zhu,P. Bombaron,Christos Chouaid,Eric Dansin,P. Fournel,G. Fraboulet,Radj Gervais,S. Hominal,S. Kahlout,H. Lecaer,Hervé Lena,J. LeTreut,C. Locher,Olivier Molinier,Isabelle Monnet,G. Oliviero,R. Schoot,P. Thomas,G. Berchem,H. Al Husaini,Francisco Aparisi,Edurne Arriola,I. Ballesteros,Isidoro Barneto,R. Bernabé,Ana Blasco,Joaquim Bosch-Barrera,V. Calvo de Juan,Enric Carcereny,Silvia Catot,Enriqueta Felip,M.-R. García-Campelo,C. García-Girón,Ramon Garcia-Gomez,R. Garcia-Sevila,A. Gasco,J. Gil,Jose-Luis Gonzalez-Larriba,S. Hernando-Polo,E. Jantus,B. Jiménez,Pilar Lianes,R. López-López,A. López-Martín,Jose Antonio Macias,J.L. Marti-Ciriquian,R. Montoyo,Daniela Morales-Espinosa,Miguel Angel Moreno,Cinta Pallares,Marta Parera,R. Perez-Carrión,R. Porta,Noemí Reguart,F. Rosillo,J.M. Sanchez,I. Sullivan,J. Terrasa,Jose Manuel Trigo,Javier Valdivia,Nuria Viñolas,Santiago Viteri,M. Botia-Castillo,José-Luis Mate,M. Perez-Cano,Josep Ramírez,B. Sanchez-Rodriguez,Miquel Taron,M. Tierno-Garcia,E. Mijangos,J. Ocaña,E. Pereira,J. Shao,X. Sun,R. O'Brate +136 more
TL;DR: The BREC studies provide proof of concept that an international, nonindustry, biomarker-directed trial is feasible and it is expected that ongoing further research on alternative biomarkers to elucidate DNA repair mechanisms will help define novel therapeutic approaches.
Journal ArticleDOI
Immunotherapy: EVALUATION OF MEMORY T CELLS AS ADOPTIVE THERAPY IN CORONAVIRUS PNEUMONIA AND/OR LYMPHOPENIA: A PHASE II CLINICAL TRIAL (RELEASE NCT04578210)
Cristina Ferreras,M. I. Martínez Hernández,Alejandro Martín-Quirós,Karima Al-Akioui-Sanz,Marta Mora-Rillo,Fatima Ibañez,R Goterris,Raquel de Paz,Pilar Guerra-García,J. Queiruga-Parada,Pablo Duarte Molina,Marisa S. Briones,Dolores Planelles,Alberto M. Borobia,Antonio J. Carcas,J. L. Vicario,Miguel Angel Moreno,Antonio Salas,Cristina Eguizabal,Bernat Soria,Carolina Mora Solano,Ariadna Pérez-Martínez +21 more
Journal ArticleDOI
A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)
Antonio Pérez-Martínez,Cristina Ferreras,M. I. Martínez Hernández,Alejandro Martín-Quirós,Karima Al-Akioui-Sanz,Marta Mora-Rillo,Fatima Ibañez,R Goterris,Raquel de Paz,Pilar Guerra-García,J. Queiruga-Parada,Pablo Duarte Molina,Merche Bou,C. Mestre-Durán,Alberto M. Borobia,Antonio J. Carcas,María Luisa Briones,Jose L. Vicario,Miguel Angel Moreno,Antonio Salas,Cristina Eguizabal,Bernat Soria,Carlos Solano +22 more
TL;DR: In this paper , a phase 2 randomized multicenter clinical trial was conducted to evaluate the safety and efficacy of the infusion of memory T cells vs the standard of care (SoC) for COVID-19 patients.